The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor | Zendy

Ryo Ko | Zendy; Hirotsugu Kenmotsu | Zendy; Yasushi Hisamatsu | Zendy; Hiroaki Akamatsu | Zendy; Shota Omori | Zendy; Kazuhisa Nakashima | Zendy; Takuya Oyakawa | Zendy; Kazushige Wakuda | Zendy; Takehito Shukuya | Zendy; Akira Ono | Zendy; Hisao Imai | Zendy; Tetsuhiko Taira | Zendy; Tateaki Naito | Zendy; Haruyasu Murakami | Zendy; Keita Mori | Zendy; Masahiro Endo | Zendy; Yasuhisa Ohde | Zendy; Kazuhisa Takahashi | Zendy; Toshiaki Takahashi | Zendy

Open Access

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

Author(s) -

Ryo Ko,

Hirotsugu Kenmotsu,

Yasushi Hisamatsu,

Hiroaki Akamatsu,

Shota Omori,

Kazuhisa Nakashima,

Takuya Oyakawa,

Kazushige Wakuda,

Takehito Shukuya,

Akira Ono,

Hisao Imai,

Tetsuhiko Taira,

Tateaki Naito,

Haruyasu Murakami,

Keita Mori,

Masahiro Endo,

Yasuhisa Ohde,

Kazuhisa Takahashi,

Toshiaki Takahashi

Publication year - 2014

Publication title -

international journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.06

H-Index - 62

eISSN - 1437-7772

pISSN - 1341-9625

DOI - 10.1007/s10147-014-0761-8

Subject(s) - gefitinib , medicine , epidermal growth factor receptor , oncology , surgical oncology , lung cancer , stage (stratigraphy) , cancer , paleontology , biology

It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutations in the epidermal growth factor receptor (EGFR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research